About tagraxofusp
CD123-directed cytotoxin
Used for
- Treats blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and children.
Usual adult dose
12 micrograms/kg intravenously once daily on days 1–5 of each 21-day cycle.
Usual dose in children
12 micrograms/kg intravenously once daily on days 1–5 of each 21-day cycle; specialist-supervised treatment.
Common side effects
- Capillary leak syndrome
- Nausea, fatigue, swelling, or weight gain
- Liver enzyme increases
- Low blood counts or infections
Important warnings
- Capillary leak syndrome can be life-threatening; monitor closely during treatment.
- Serious infusion reactions and liver toxicity may occur.
- Treatment requires specialist monitoring and preventive measures, including medicines before infusion.
- Avoid treatment during active serious infection; report fever promptly.
Pregnancy
May cause fetal harm. Effective contraception is recommended during treatment and for one week after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- No major established drug interactions; the effects of other medicines are not well characterized.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.